| 摘要 |
Methods of treating neuroinflammation by administration of a selective protein C activator, such as recombinant human WE thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions for use in the treatment of mammals that exhibit symptoms of neurological inflammation. The pharmaceutical compositions and pharmacological dose comprise a safe and effective amount of WE thrombin. |
